Tomasz Ożański (T Ożański)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 2

Top Topics

Coronavirus Disease

Top Venues

Leukemia & lymphoma

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Magdalena Olszewska-Szopa, Agnieszka Ożańska, Tomasz Ożański, Justyna Rybka, Tomasz Wrobel
The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience. Leukemia & lymphoma (2023)
Johannes Bracher, Daniel Wolffram, Jannik Deuschel, Konstantin Görgen, Jakob L Ketterer, Alexander Ullrich, S Abbott, M V Barbarossa, D Bertsimas, Sangeeta N Bhatia, Marcin Bodych, Nikos I Bosse, Jan Pablo Burgard, Lauren A Castro, Geoffrey Fairchild, J Fuhrmann, Sebastian Funk, Krzysztof Gogolewski, Quanquan Gu, Stefan Heyder, T Hotz, Y Kheifetz, Holger Kirsten, T Krueger, Ekaterina Krymova, Michael Lingzhi Li, Jan H Meinke, Isaac J Michaud, K Niedzielewski, Tomasz Ożański, F Rakowski, Markus Scholz, Saksham Soni, Ajitesh Srivastava, Jakub Zielinski, D Zou, T Gneiting, Melanie Schienle, null null
A pre-registered short-term forecasting study of COVID-19 in Germany and Poland during the second wave. Nature communications 12 (1) (2021)